Oesophageal adenocarcinoma stage III

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-1) 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB
    2023-509360-24-00 10 countries 2016 n=275
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
← All indication landscapes